





## ASCO's Quality Training Program

### Navigating Stage IV Patients to Reduce Emergency Room admissions

Carlos F. Pinto, MD Fernanda Loiola, MD Henrique Fernandes, MD Stela Coelho, MS, MBA Shubham Pant, MD – QTP Improvement Coach

Instituto de Oncologia do Vale

October 4, 2017





## **IOV GROUP Overview**

Private Medical Group with 6 outpatient facilities in two cities covering outpatient cancer care for ~ 60% of our metropolitan area with 2.4 M inhabitants. Accreditation by Brazilian National Accrediting Organization Excellence, by Accreditation with one QOPI<sup>®</sup> Certified Practice.

- ~200 employees and associates;
- 18 physicians: Clinic Onc, Rad Onc, Hem Onc;
- ~ 60,000 medical appointments/year;
- ~ 650 patients procedures/day.





## Canada and



## Problem Statement

In 2016, Stage IV Patients at IOV-SJC had a monthly average ratio\* of **3.8 admissions to Emergency Room** (ER).

More than 70% of these complaints are potentially manageable. These ER admissions worsen patients' experience of care, increase global costs and can impact their quality of life (QoL).

Pain, constipation, fever, fatigue, nausea/vomiting, diarrhea and dehydration are the clinical conditions that we consider as "manageable or preventable ER admissions".

\* Stage IV Patients ER Admission / Total Chemo Patients (monthly)







## Team Members

Role	Name	Job Fund
Project Sponsor#	Leo Altoé, RN, MBA	Site Manag
Team Leader+	Carlos (Fred) Pinto, MD	Executive [
Core Team Member*	Henrique Z. Fernandes, MD	Medical Dir
Facilitator*	Stela Maris Coelho, MS, MBA	Lean Office
Core Team Member*	Fernanda Loiola, MD	Palliative C
QTP Improvement Coach	Shubham Pant, MD	Provides re team
<b>Operational Members</b>	Elisangela Romano, RN, Michele Felix, RN, Laura Gomes, RN	Members in and testing
<b>Operational Members</b>	Janaina Ferreira, MBA Luiz Artur Correa, MD	Insurance ( (SulAmerica
Patient/Family	Margarete and Eduardo Camurça	Patient and





### ction

### jer IOV-SJC

- Director IOV Group
- rector IOV Group
- Mngr IOV Group
- are, IOV
- mote support to the
- nvolved in developing
- change
- Company
- a) support team
- husband





## Cause & Effect/ Fishbone Diagram





American Society of Clinical Oncolog

## Diagnostic Data 1 Pareto for ER admissions: symptoms and complaints



### **Comments:**

- The most frequently identified complaint at ER is Pain. We have no data to better **a**. define "supportive care" admission, in some occasion it is also related to pain;
- **b.** Data quality is weak, it was collected during patient appointments.







## Diagnostic Data 2 (Voice of the Customer)

- We conducted several VOC sessions to identify:
  - How we could provide better care?
  - If patients are willing to pay for 24/7 phone services?
  - What leads patients to an ER?
  - Brainstorm with nurses: what patients complaint most by phone?
  - Clearly define what problem we are trying to solve to our patients
- The patient problem defined by the customer: "I don't know what to do when I'm not doing well"







## Diagnostic Data 3 Patients Treated Monthly: Potential bias to evaluate ER admissions



### **Comments:**

- a. The median number of monthly chemo patients from 2016 to 2017 increased by 16%;
- b. This variation can introduce bias in future measurements and should be considered.





### ' increased by 16%; Id be considered.





American Society of Clinical Oncology

## **Diagnostic Data 4 Timeline of Data Collection** Cohort 2 Cohort 1

(pain management) (control) Aug 2016 - Aug 2017 Jan 2016 – Aug 2016 **Data Collected: Data Collected:** 

- **ER** admissions for Stage IV deceased patients between Jan16 and Aug16
- **Symptoms** associated with ER admission

- ER admissions for **Stage IV deceased** patients
- Symptoms associated with ER admission **Project Launch**:
- VOC
- Data collect
- **Standards**

**Data Collected: ER** admissions for 

- Stage IV





Cohort 3 (palliative care management)

### Sep 2017 – Apr 2018

### deceased patients Symptoms associated with ER admission





American Society of Clinical Oncole

## **Baseline Data** Stage IV ER admissions/total chemo patients



Months

### **Comments:**

- a. Evaluate Stage IV ER admission ratio to total chemo patients can be one way to reduce bias due total chemo patients fluctuation.
- b. We will use this ratio as our baseline data.











American Society of Clinical Oncolog





SBAR

Hospice?



## By April 2018 we expect to reduce by 30% ER admissions for Stage IV Patients when comparing cohort 1 to 3.









American Society of Clinical Oncology

## Measures

- **Measure:** 
  - Number of ER admissions

### **Patient population:** ۲

- Stage IV patients; ٠
- 3 comparision cohorts.

### **Calculation methodology:** ٠

Average ER admissions ratio for the above ٠ patient population.

### **Data collection frequency:**

Monthly, using deceased patient charts + ulletreported triggers and Coordinated Care notes for ER admissions.

### **Data source:**

- Retrieve active report for ER admissions in ulletpatient charts
- Patient Navigation System records lacksquare

### **Data Quality (limitations):**

- **ER admission data is weak:** it is mannually  $\bullet$ collected during medical appointments.
- There is **no integrated EMR with ERs**, and our ulletpatients can go to more than 5 different ERs.
- An increasing number of patients are being • admitted for chemo at IOV.







## Action Plan

Date of PDSA Cycle	Description of Intervention	Results	
PDSA #1: 06/12/2017 08/23/2017	<ul> <li>NURSE EDUCATION &amp; TRAINING</li> <li>Standard Work Protocols (SW) to manage symptoms:</li> <li>Review current SW and create new ones: Pain, Mucositis, Nausea and Vomiting, Fever, Diarrhea, Mental Confusion and Syncope, Fatigue, Dyspnea and Inappetence;</li> </ul>	SW tested and ok: Pain, Mucositis, N&V, Fever, Fatigue, Diarrhea, SW not feasible: Inappetence (merged with fatigue) Dyspnea (too complex – treat as special variation)	•
PDSA #2: 06/22/2017 08/31/2017	<ul> <li>PATIENT EDUCATION MATERIAL</li> <li>Reviewing the patient educational materials: printed, online and verbal.</li> </ul>	Not fully developed, still ongoing	•
PDSA #3: 06/22/2017 08/31/2017	<ul> <li>CHAT</li> <li>Define tool and create a CHAT;</li> <li>Use SW (PDSA 1+2) and Test chat;</li> <li>Provide pilot access for 10 patients.</li> </ul>	Patients considering too complicated to access chat. Chat robots are not being helpful.	•
PDSA #4: 09/01/2017 09/30/2017	<ul> <li>Go live with SW developed in PDSA 1+2 and provide dedicated access by phone to all patients.</li> <li>Evaluate working hours of services and Weekend support</li> <li>Improve data quality</li> </ul>	Regular working hours seem to be enough to provide proposed care. Developing a special plan for Fridays and holidays	•





### **Action Steps**

PDSA: trial use with 10 patients - pain in a separated flow (ongoing since Aug 2016); Education/training material will be provided to PDSA cycle 4

Education material will be provided to PDSA cycle 4

Create a new channel for phone service (cellular) for patients. **ABANDONED** 

All stage IV patients (pain included) Plan to Fridays and holidays Change data collection methods A

American Society of Clinical Oncology

## **Prioritized List of Changes** (Priority/Pay – Off Matrix)

Impact



**Ease of Implementation** 





**PDSA #4** 09/01/17





# PDSA #1 + #2: Nurse Training, New Standards + Patient Education

### Development: 8 weeks Test period: 06/22/17 to present

• New standards to be used in all patient contact refering complaints;

### **Results**:

- Nurses refers they are easier to use than the ones used before:
  - Faster to identify critical issues;
  - Single paged, straight flow of care
  - All needed steps included as one cycle of care;
  - Most frequent prescribed countermeasures and procedures included.

REPUTO I PROLOGIA	MUCOSITE		
	TIQUETA DE IDENTIFICAÇÃO PA	ACIENTE	
PASSO 1:			
Data: / /Hora: Outros medicamentos em us	Protocolo:	Ciclo atual:	
PASSO 2: Analise se o me Principais:	dicamento que está em uso tem	relação com a mucosite:	
5-FU DOXORRUB		ETOPOSIDE BLEOMICINA	
	FALAN OUTROS		
PASSO 3: Analise o grau da mucosite Hora 0			
Por () Não () Sim - ()	2008: () Não (_) Sim		
Affas (ükerasi ( ) Não ( )	Sim Obs:		
Dieta ( ) Normal ( ) Pas	tosa () Líquida () Nenhuma		
<u>Eebre_(</u> )Não () Sim Temperatura informada°C			
GRAU DESCRIÇÃO	DOS SINAIS DESCRI	IÇÃO DOS SINTOMAS / FUNÇÃO	
( )1 Eritema	Sintomas mi	nimos / dieta normal	
( ) 2 Ulcerações/ Pseudon moderada	rembranas, dor Sintomático, modificada	, mas pode beber / comer dieta	
( ) 3 Ulcerações/ Pseudon confluentes ou sangr trauma, dor severa	vembranas Sintomático amento ao menor hidratação a	e incapaz de receber dieta ou dequadamente	
( ) 4 Necrose / sangramen de vida	to espontâneo risco Sintomas ass internencio	sociado com risco de vida, indicada	







### PDSA #1 + #2: Materials in use/Developed (samples) ia Bem Viver

Þ	PASSO 4: Orientações realizadas		
	RECOMENDAÇÕES NUTRICIONAIS GERAIS	<ul> <li>( ) Evite alimentos duros, salgados, ácidos, picantes ou secos e vegetais crus</li> <li>( ) Utilize alimentos à temperatura ambiente, fria ou gelada</li> <li>( ) Modifique a consistência da dieta de acordo com o grau de mucosite</li> </ul>	
	MUCOSITE GRAU 1	<ul> <li>( ) Oncilon A em Orabase - passar 3-4x/dia</li> <li>( ) Cioridrato de benzidam/da - colutório 3 ou + bochechos/ao dia - 1 medida pura ou diluída em pouca água.</li> <li>( ) Lidocalha 2% spray - aplicar antes das refeições se tiver dor ao se alimentar.</li> <li>( ) Laser de Baixa Potência - CCP em RT e QT</li> </ul>	
	MUCOSITE GRAU 2	<ul> <li>( ) Recomendações nutricionais e medidas para grau 1</li> <li>( ) Analgésicos – Dipirona 500mg ou Paracetamol 500mg de 6/6h</li> <li>( ) Prednisona 10-20mg/dia por 4 dias</li> <li>( ) Laser de Baixa Potências - CCP</li> </ul>	
	MUCOSITE GRAU 3	<ul> <li>( ) Recomendações nutricionais e medidas para grau 1 e 2</li> <li>( ) Solicitado ao médico avaliação para associar opióide</li> <li>(Codeinalmorfina). Qual:</li> <li>( ) Solicitado ao médico avaliação da necessidade de nutrição enteral</li> <li>( ) Solicitado ao médico avaliação para realização de hemograma.</li> </ul>	
	MUCOSITE GRAU 4	<ul> <li>( ) Orientado para procurar pronto socorro e solicitar avaliação de Internação hospitalar</li> </ul>	

### PASSO 5: Seguimento

Observações:

\_\_\_\_\_

Contato	Avallação	Conduta
	Dor: 🛓 ) sim ( ) não	
Z4 Horas	Dieta: 📥 ) normal 🔹 ) modificada	
	Aumento das Lesões 🛁 ) sim ( ) não	
	Dor: 👍 ) sim ( ) não	
48 Horas	Dieta: 📥 ) normal 🛛 ( 🔄 ) modificada	
11	Aumento das Lesões;≟ ) sim ( ) não	
	Dor: 👍 ) sim ( ) não	
72 Horas	Dieta: 👝 ) normal 🛛 ( 🔄 ) modificada	
1.1	Aumento das Lesões🥁 🛛 sim 🕧 não	

Enfermeira Responsável

Bem Viver

**Efeitos Colaterais** dos Medicamentos







- · Alimentos ricos em fibras;
- Ingestão de água;
- · Atividade física;
- · Não use laxante por conta própria;
- Informe ao médico.



### Segmented E-learning + Printed materials

### NÁUSEAS E VÔMITO

- Faça refeições pequenas;
- ⇒ Tome líquidos em quantidades fracionadas;
- ⇒ Chupe pedras de gelo;
- ⇒ Siga a prescrição do seu médico;





American Society of Clinical Oncolog

# PDSA #3: Chat with patients to evaluate symptoms/complaints

### Test period: 06/22 to 08/31/17 Live: 3 weeks for patients Results:

- Customers considered chats too complicated to access.
- Chat robots developed were not being helpful, nurses always needed to call back.
- Abandoned.





## **PDSA #4: Dedicated Phone Access**

### **Test period: 8 weeks** (09/01 - 10/31/17)**Results:**

Project flyer w/ Dedicated Phone number

- 12 h availability might not be needed, evaluation ongoing.
- Most calls come in before noon.
- New complaints are being tracked to consider new standards, if needed.

### **Ongoing**:

**IMPROVE DATA COLLECTON METHODS** 

Para melhor atendê-lo, o IOV estará disponibilizando um novo canal de atendimento telefônico, para pacientes em tratamento quimioterápico.

Caso esteja apresentando sintomas de difícil controle, entre em contato com a nossa equipe pelo número (12) 99623-9273, de segunda a sexta-feira, das 8h às 18h.

Observação: Esse canal não realiza agendamento de consultas e solicitação de exames.







### CUIDADO COORDENADO IOV

Tenha em mãos o Guia Bem Viver, o número do prontuário e a data de realização da última quimioterapia.





## PDSA #4: Dedicated Phone Access **Initial Data**



### Number of calls 09/01/2017 - 09/22/2017

### **Comments:**

- Most calls are until noon;
- No calls after 6 PM (no need for after hours availability?).







## PDSA #4 Data Analysis Patient symptoms/complaints phone calls

### Number of Calls for Coordinated Care 05/29/17 to 09/22/17



### **Comments:**

- This data includes pain navigation system calls;
- Some new complaints emerged like "cough (flu?)" and "urinary tract infection".









American Society of Clinical Oncology

## Conclusions (where we are now)

Achievements:

- Improved, safer and simplified standards for symptoms/side effects management;
- **Better integration** between care nurse, triage and coordinated care (Navigation System);
- Better understanding of customers needs;
- Faster and easier patient access to manage symptoms and other complaints.









## Lessons Learned (up to this point)

- Include patient and husband was critical to establish our real AIM, many of our assumptions were not relevant to patients;
- Provide good quality informations sometimes means: *"provide*" *less, but critical information"*, sometimes patients get confused with too much information;
- Active education and clear standards helped to improve care provided by all IOV teams;
- Small paced changes/pilots gave us opportunity to save resources and provide services as demanded by the customer.









## Next Steps/Plan for Sustainability

- EXECUTE PDSA #4
  - Evaluate the extent of services provided (12h or 8h?; weekends?);
  - Improve data collection methods to get more accurate information about ER admissions;
  - Adjust current standards: exclude/include/merge actual ones as needed;
  - Standardize improvements into daily safety and flow huddles.









### **Project Title: Navigating Palliative Care Patients to Reduce Emergency Room**

AI	AIM: By December 2017 we expect to reduce 30% ER admissions Stage IV Patients	
IN 1. 2. 3. <b>4.</b>	TERVENTION: Standard Work for Nurses/Physicians to manage common symptoms/complaints, PDSA #1+2 Educational material for patients, PDSA #1+2 Patient Chat for online management, PDSA #3 (abandoned) Dedicated phone access to stage IV patients following new standards, PDSA #4, data collection from 09/01/17 to 04/30/18.	

<b>RESULTS:</b> Should be related to your AIM statement. Be sure to title the graph, identify	CONCLUSIONS:
the SPC chart used, label the x & y axis, include a legend	<ul> <li>Dedicated phon management an associated.</li> </ul>
Graph title	<ul> <li>PDSA #4 is evalu symptoms by ph admissions</li> </ul>
Insert graph	NEVT STEDS.
	<ul> <li>Consider to inclu</li> <li>Improve quality the involved tea</li> <li>Update SW (star</li> </ul>

### EAM: Instituto de Oncologia do

ale : Carlos F. Pinto, MD enrique Z. Fernandes, MD tela Maris Coelho, MS, MBA ernanda Loiola, MD ulAmerica : Janaina Ferreira, IBA, Luiz A. Correa, MD **DV Patients:** Margarete and duardo Camurça ROJECT SPONSORS: Leo Altoé, N, MBA, Site Manager

one access improved pain and reduced ER admissions pain

luating if managing other phone can reduce even further ER

clude ALL IOV chemo patients ty of ER admissions data using eam (current data is confusing) andards) for all patients

